Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/24872
Full metadata record
DC FieldValueLanguage
dc.contributor.authorErnst Rüdiger Kuseen_US
dc.contributor.authorPloenchan Chetchotisakden_US
dc.contributor.authorClovis Arns da Cunhaen_US
dc.contributor.authorMarkus Ruhnkeen_US
dc.contributor.authorCarlos Barriosen_US
dc.contributor.authorDigumarti Raghunadharaoen_US
dc.contributor.authorJagdev Singh Sekhonen_US
dc.contributor.authorAntonio Freireen_US
dc.contributor.authorVenkatasubramanian Ramasubramanianen_US
dc.contributor.authorIgnace Demeyeren_US
dc.contributor.authorMarcio Nuccien_US
dc.contributor.authorAmorn Leelarasameeen_US
dc.contributor.authorFrédérique Jacobsen_US
dc.contributor.authorJohan Decruyenaereen_US
dc.contributor.authorDidier Pitteten_US
dc.contributor.authorAndrew J. Ullmannen_US
dc.contributor.authorLuis Ostrosky-Zeichneren_US
dc.contributor.authorOlivier Lortholaryen_US
dc.contributor.authorSonja Koblingeren_US
dc.contributor.authorHeike Diekmann-Berndten_US
dc.contributor.authorOliver A. Cornelyen_US
dc.contributor.otherKlinik für Viszeral- und Transplantationschirurgieen_US
dc.contributor.otherKhon Kaen Universityen_US
dc.contributor.otherR Desembargador Vieira Cavalcanteen_US
dc.contributor.otherCharité – Universitätsmedizin Berlinen_US
dc.contributor.otherPontificia Universidade Catolica do Rio Grande do Sulen_US
dc.contributor.otherNizam's Institute of Medical Sciencesen_US
dc.contributor.otherDayanand Medical College and Hospitalen_US
dc.contributor.otherSanta Casa de Belo Horizonteen_US
dc.contributor.otherApollo Hospitalsen_US
dc.contributor.otherOnze Lieve Vrouw Hospitalen_US
dc.contributor.otherUniversidade Federal do Rio de Janeiroen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherHospital Erasmeen_US
dc.contributor.otherUniversity Hospital of Ghenten_US
dc.contributor.otherHopitaux universitaires de Geneveen_US
dc.contributor.otherKlinikum der Johannes-Gutenberg-Universitat und Fachbereich Medizinen_US
dc.contributor.otherUniversity of Texas Medical School at Houstonen_US
dc.contributor.otherHopital Necker Enfants Maladesen_US
dc.contributor.otherAstellas Pharma GmbHen_US
dc.contributor.otherUniklinik Kolnen_US
dc.date.accessioned2018-08-24T02:05:47Z-
dc.date.available2018-08-24T02:05:47Z-
dc.date.issued2007-05-05en_US
dc.identifier.citationLancet. Vol.369, No.9572 (2007), 1519-1527en_US
dc.identifier.issn01406736en_US
dc.identifier.other2-s2.0-34247564562en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=34247564562&origin=inwarden_US
dc.identifier.urihttp://repository.li.mahidol.ac.th/dspace/handle/123456789/24872-
dc.description.abstractBackground: Invasive candidosis is increasingly prevalent in seriously ill patients. Our aim was to compare micafungin with liposomal amphotericin B for the treatment of adult patients with candidaemia or invasive candidosis. Methods: We did a double-blind, randomised, multinational non-inferiority study to compare micafungin (100 mg/day) with liposomal amphotericin B (3 mg/kg per day) as first-line treatment of candidaemia and invasive candidosis. The primary endpoint was treatment success, defined as both a clinical and a mycological response at the end of treatment. Primary analyses were done on a per-protocol basis. This trial is registered with ClinicalTrials.gov, number NCT00106288. Findings: 264 individuals were randomly assigned to treatment with micafungin; 267 were randomly assigned to receive liposomal amphotericin B. 202 individuals in the micafungin group and 190 in the liposomal amphotericin B group were included in the per-protocol analyses. Treatment success was observed for 181 (89·6%) patients treated with micafungin and 170 (89·5%) patients treated with liposomal amphotericin B. The difference in proportions, after stratification by neutropenic status at baseline, was 0·7% (95% CI -5·3 to 6·7). Efficacy was independent of the Candida spp and primary site of infection, as well as neutropenic status, APACHE II score, and whether a catheter was removed or replaced during the study. There were fewer treatment-related adverse events-including those that were serious or led to treatment discontinuation-with micafungin than there were with liposomal amphotericin B. Interpretation: Micafungin was as effective as-and caused fewer adverse events than-liposomal amphotericin B as first-line treatment of candidaemia and invasive candidosis. © 2007 Elsevier Ltd. All rights reserved.en_US
dc.rightsMahidol Universityen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=34247564562&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleMicafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trialen_US
dc.typeArticleen_US
dc.rights.holderSCOPUSen_US
dc.identifier.doi10.1016/S0140-6736(07)60605-9en_US
Appears in Collections:Scopus 2006-2010

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.